🌟 Curious about how our unique ZTX® platform works? 🤔 Click on the video link below and prepare to be amazed at how you, and the entire pharmaceutical industry, can benefit from this groundbreaking technology. 👇🎥 Would like to dive deeper into the details? Don't hesitate to reach out. We're here to answer your questions and explore the possibilities together! 🚀💬 📧 [email protected] 🌐 www.bioreperia.com #ZTXPlatform #PharmaInnovation #Bioreperia #UnlockingPotential #Zebrafish #Oncology #Clinicaldevelopment #Precisionmedicine #Healthcare #Drugdiscovery
BioReperia
Forskning inom bioteknik
Linköping, Ostergotland County 2 546 följare
Accelerating drug discovery and predicting the best cancer treatment for you!
Om oss
With our unique ZTX® platform (zebrafish tumor xenograft), it's possible to accelerate drug discovery and determine the best drug available for each patient within a few days. BioReperia is a Swedish contract research organization (CRO) developing new products to accelerate drug discovery, improve the diagnosis of cancer patients, and increase the success rate in clinical trials using zebrafish models. Our proprietary platform reduces the prediction time for the right anti-cancer treatment in individual cancer patients from 6 months to 5 days. It also allows metastasis invasion within 3 days, providing in vivo data on tumor regression and metastasis inhibition of compounds in less than a week. As an agile and highly customizable toolbox for drug discovery, our product can be applied to all cancer indications, using cell lines and patient-derived xenografts, as well as primary tumors from patients. This platform can accommodate all types of compounds, from small molecules to large peptides, antibodies, and ADCs. Additionally, it has been developed to include the evaluation of immuno-therapies. Why not save time and financial resources by having an in vivo model that accurately identifies drug candidates in less than a week? Learn more about our lead products for precision medicine (ZTX®Predict) and drug discovery (ZTX®Oncoleads). We are happy to discuss how we can collaborate. Please contact us at [email protected].
- Webbplats
-
http://www.BioReperia.com
Extern länk för BioReperia
- Bransch
- Forskning inom bioteknik
- Företagsstorlek
- 2–10 anställda
- Huvudkontor
- Linköping, Ostergotland County
- Typ
- Privatägt företag
- Grundat
- 2015
- Specialistområden
- Oncology, Drug Discovery, Toxicology, Zebrafish, Clinical Trials, PDX models, Precision medicine, Drug development, CDX models, Immunotherapy, Patient stratification, Lead optimization, Target validation och Screening
Adresser
-
Primär
Få vägbeskrivning
Westmansgatan
47
Linköping, Ostergotland County 58216, SE
-
Få vägbeskrivning
Linköping University, Campus US
Linköping, Ostergotland County 58165, SE
-
Få vägbeskrivning
Liestal , CH
Anställda på BioReperia
Uppdateringar
-
🌐 Greetings from Malmö! 🌐 Exciting times at #NLSdays2024! Don’t miss the chance to connect with our CEO, Anna Erkstam, who is attending the Nordic Life Science Days. 🤝 Eager to discover how our highly translatable in vivo model can accelerate #drugdiscovery by delivering key data on #tumorregression and #metastasis dissemination in just 5 days? 🐟 Reach out to Anna for valuable insights and engaging discussions! ✨ 📧 [email protected] 🌐 www.bioreperia.com #LifeSciences #Networking #Biotech #Pharma #Zebrafish #PrecisionMedicine #Innovation #BioReperia #Oncology #TeamBioreperia #ClinicalDevelopment #Healthcare #CustomerRelations #CustomerDevelopment #DrugDiscovery #DrugDevelopment
-
-
Join us in this webinar to discover the latest research of EVs on cancer metastasis, and how our zebrafish tumour xenograft model can provide a new in vivo solution for the evaluation and development of EVs-based therapeutic strategies targeting cancer cell dissemination in just three days. 🌐 Register now at: https://lnkd.in/dNRdCeyy
BioReperia Webinar: Extracellular vesicles in cancer research
www.linkedin.com
-
BioReperia omdelade detta
Extracellular vesicles (#EVs) are important mediators of #intercellular communication. Due to in vivo evaluation challenges, EVs' cellular and #molecular mechanisms in #cancer #metastasis remain far from fully understood. #Mouse models are costly, and visualization of metastasis is time-consuming. Thus, fast and cost-effective in vivo models that #accurately recapitulate cancer metastasis are needed. In this webinar, we will dive deep into the latest research of EVs on cancer metastasis and how in vivo solutions, such as the #zebrafish tumour #xenograft #model, can bridge the knowledge gap and address key research questions about the role of EVs on cancer #cell dissemination in just three days. Dr. Linda Bojmar from Linköping University and our CTO and co-founder, Lasse Jensen, will be the keynote speaker, moderated by our colleague Zaheer Ali. Please join us for our #webinar 📅 25th September, 2024 ⏰ 4PM CET 🌐 Register now at: https://lnkd.in/dNRdCeyy #Webinar #BioReperia #ExtracellularVesicles #Zebrafish #TumorXenograft #BioReperiaTeam
-
-
Extracellular vesicles (#EVs) are important mediators of #intercellular communication. Due to in vivo evaluation challenges, EVs' cellular and #molecular mechanisms in #cancer #metastasis remain far from fully understood. #Mouse models are costly, and visualization of metastasis is time-consuming. Thus, fast and cost-effective in vivo models that #accurately recapitulate cancer metastasis are needed. In this webinar, we will dive deep into the latest research of EVs on cancer metastasis and how in vivo solutions, such as the #zebrafish tumour #xenograft #model, can bridge the knowledge gap and address key research questions about the role of EVs on cancer #cell dissemination in just three days. Dr. Linda Bojmar from Linköping University and our CTO and co-founder, Lasse Jensen, will be the keynote speaker, moderated by our colleague Zaheer Ali. Please join us for our #webinar 📅 25th September, 2024 ⏰ 4PM CET 🌐 Register now at: https://lnkd.in/dNRdCeyy #Webinar #BioReperia #ExtracellularVesicles #Zebrafish #TumorXenograft #BioReperiaTeam
-
-
Do you know that we can use the ZTX platform to #predict #metastasis dissemination? 🚀 In just 3 days, we deliver highly #accurate and #translatable in-vivo data, empowering your research and clinical practice with cutting-edge insights. 🔬 🎥 Hear from our CTO, Lasse Jensen in a fish-flash 1-minute talk about how we're advancing #cancer #research! 🐟 Don’t hesitate to contact us 😊 We are happy to explain more about how our #platform can #accelerate your #drugdiscovery and #predict metastasis. #CancerResearch #PrecisionMedicine #MetastasisPrediction #ZTXPlatform #BiotechInnovation #InVivoData #CTOInsights #Zebrafish #BioReperia
-
🌟 Exciting News! 🌟 We are thrilled to share that BioReperia has recently initiated a new collaboration, empowering us to conduct projects using patient-derived cells. This advancement enhances our capabilities and opens up new avenues for innovation in our research and services. Are you interested in using patient-derived cells in your next in-vivo study? 🎗️ 🐟 We would be delighted to share more details about how our new capabilities can support your company! Let’s connect and explore the possibilities together! 🤝 #BioReperia #Collaboration #PatientDerivedCells #PDCs #Glioblastoma #Innovation #DrugDevelopment #PrecisionMedicine #Oncology
Evaluation and commercial use agreement announcement. We are pleased to confirm the execution of an evaluation and commercial use agreement with Swedish contract research organisation BioReperia. This is the first commercial agreement for the use of Inaphaea’s Patient Derived Cells (PDCs) which centres on their use in BioReperia’s advanced in-vivo ZTX® platform for drug development. This collaboration will offer expanded services for glioblastoma models, with the potential to include more cancer types from Inaphaea’s extensive bank of 470 PDCs. This is an important first step in expanding the market for Inaphaea’s PDC bank as a product, in parallel with the service element of the business. Read more about the agreement here: https://lnkd.in/e-XzpQrb #PDCs #BioTech #DrugDiscovery #Assays #AssayDevelopment
-
-
🇫🇷 From the land of the Olympics to Sweden! 🇸🇪 🤸♀️ This summer, we had the pleasure of hosting Sofia Billault for a three-month internship at BioReperia. Sofia is about to begin her final year of engineering studies at École Polytechnique near #Paris, #France, where she majors in #biology. Reflecting on her experience, Sofia shared: "I had the wonderful opportunity to apply my knowledge and learn so much more during my #internship at BioReperia. I am very grateful for this experience and inspired to pursue a #career in #biotechnology." It's always exciting to have fresh perspectives from bright, young minds. We're grateful for the energy and insights Sofia brought to our #team! #Internship #Biotechnology #Innovation #Engineering #BioReperia #Oncology #Zebrafish #PrecisionMedicine #DrugDiscovery #DrugDevelopment
-
-
BioReperia omdelade detta
With great pleasure, we are posting the first preprint of our collaborative effort of automation of the zebrafish xenograft assay. With ZeClinics, BioReperia and Centre for Molecular Medicine Norway (NCMM), University of Oslo
-
🎉 We’ve reached 2.5K followers! 🎉 Each of you plays a crucial role in our mission to reduce cancer mortality and advance drug discovery. Your engagement—whether through likes, shares, or comments—helps amplify our message and brings us closer to a future with better, personalized cancer treatments. 🙌 Thank you for your ongoing support. Together, we’re making a real difference in the field of oncology! 🚀 🌟 #Oncology #CancerResearch #2.5K #AIImage
-
Liknande sidor
Finansiering
BioReperia
2 rundor totalt
Se mer info på crunchbase
Senaste finansieringsrunda
Serie A
Extern Crunchbase Link för sista finansieringsrundan
830 664,00 US$